Antifibrotic agent 4
Antifibrotic agent 4 is an antifibrotic agent. Antifibrotic agent 4 inhibits the expression of the fibrotic markers α-SMA and COL1A1 in hepatic stellate cells by binding to FGFR4 and reducing its autophosphorylation, ameliorates liver injury and collagen deposition in mouse models of liver fibrosis, and does not inhibit the hERG potassium channel. Antifibrotic agent 4 can be used in the research of liver fibrosis.
For research use only. We do not sell to patients.
- Formula: C29H35Br4N3O6
- Molecular Weight:841.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LX-2 | IC50 |
12.612 μM
|
Inhibition of viability of TGF-β-activated hepatic stellate LX2 cells incubated for 24 h by MTT cell viability assay.
Inhibition of viability of TGF-β-activated hepatic stellate LX2 cells incubated for 24 h by MTT cell viability assay.
|
42593910 |
In Vitro
Antifibrotic agent 4 (compound C11) exhibits extremely weak inhibitory effect on the hERG potassium channel, with an IC50 value of > 100 μM, which eliminates the cardiotoxicity risk of the parent compound PD[1].
Antifibrotic agent 4 (10-20 μM; 24 h) inhibits the viability of activated LX2 cells, with an IC50 of 12.61 μM. It also reduces the expression of fibrosis markers and suppresses FGFR4 phosphorylation, retaining antifibrotic activity in vitro[1].
Antifibrotic agent 4 (1.5-400 μM) exhibits no toxicity to normal AML12 hepatocytes, and may promote the proliferation of these cells at concentrations of 13 μM and 25 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TGF-β-activated hepatic stellate LX2 cells
-
Concentration:10, 20 μM
-
Incubation Time:24 h
-
Result:Inhibited viability of activated LX2 cells with an IC50 of 12.612 μM.
Dose-dependently reduced protein expression of fibrosis markers α-SMA and COL1A1.
Reduced autophosphorylation of FGFR4 (p-FGFR4) in activated LX2 cells.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | T1/2 | MRTINF_obs | Tmax | Cmax |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 5 mg/kg | i.p. | 589 ng/mL·h | 592 ng/mL·h | 0.427 h | 0.87 h | 0.250 h | 904 ng/mL |
In Vivo
Antifibrotic agent 4 (10-50 mg/kg; i.p.; administered daily for 14 consecutive days) exhibits no observable in vivo toxicity in mice at doses up to 50 mg/kg with daily administration for 14 consecutive days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CCl4-induced liver fibrosis in 6-week-old mice[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; once daily; 2 weeks
-
Result:Significantly improved liver index at 5 mg/kg and 10 mg/kg doses.
Reduced serum transaminase (ALT, AST) levels at 5 mg/kg and 10 mg/kg doses.
Attenuated hepatic inflammatory infiltration at 5 mg/kg and 10 mg/kg doses.
Reduced collagen deposition (confirmed via H&E, Masson, and Sirius Red staining) at 5 mg/kg and 10 mg/kg doses.
Exhibited inhibitory effect on hepatic α-SMA protein expression comparable to parent compound PD at 10 mg/kg.
Reduced hepatic Acta2 and Col1a1 mRNA levels at 10 mg/kg.
-
Animal Model:acute toxicity testing[1]
-
Dosage:10 mg/kg; 30 mg/kg; 50 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Caused no mortality at any tested dose.
Had no adverse effects on body weight, heart index, spleen index, lung index, or kidney index.
Maintained serum levels of CRE, BUN, AST, and ALT within normal ranges.
Showed no histopathological abnormalities in heart, liver, spleen, lung, or kidney tissues.
Chemical Information
-
Molecular Weight 841.22
-
Formula C29H35Br4N3O6
-
SMILES
BrC1=C(OCCCNC(C)=O)C(Br)=CC(C2C(C2)C(N(C)CCCOC3=C(Br)C=C(OCC(N(C)C)=O)C=C3Br)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Antifibrotic agent 4
- Antifibrotic agent4
- Antifibrotic agent-4
- Biochemical Assay Reagents
- CCl4-induced liver fibrosis
- COL1A1
- liver fibrosis mouse models
- Fibroblast Growth Factor Receptor 4
- AML12 normal hepatocytes
- α-SMA
- activated hepatic stellate cells
- hepatocytes
- LX2 cell
- hERG potassium channel
- Inhibitor
- inhibitor
- inhibit